MTG

Mission Statement

​

The Mitochondrial Therapies Group (MTG) brings together chemists, biochemists and clinicians to enable rational design, synthesis and testing of novel diagnostic and therapeutic compounds that target mitochondria. Our aim is to use these compounds to understand and prevent common pathologies where mitochondrial dysfunction occurs such as ischaemia-reperfusion (IR) injury, cancer, diabetes and inflammatory disorders. Compounds that the MTG has developed have had notable success in limiting IR injury in in vivo models of heart attack, organ transplantation and stroke. Although we aim to understand the underlying pathology the MTG is focused on translational research that can bring novel therapies from bench to bedside in a timely fashion for disorders that affect our ageing populations.